Drugs / TVC-PR1
last change Jan 2009 re-read 2 minutes ago

TVC-PR1

Vaccine

Developed for
myelodysplastic syndrome
Investigated by
The Vaccine Company

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00513578 Jan 2007 → Jan 2009 myelodysplastic syndrome The Vaccine Company Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TVC-PR1 “proteinase PR1 leukemia peptide vaccine (TVC-PR1)” NCT00513578
Modality Vaccine “PR1 leukemia peptide vaccineNCT00513578
Route Subcutaneous “4 subcutaneous injections of PR1 leukemia peptide vaccine formulated in incomplete Freund's adjuvant (IFA)” NCT00513578